270 related articles for article (PubMed ID: 12586669)
21. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
23. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
24. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
[TBL] [Abstract][Full Text] [Related]
25. Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end.
Lansley M; Bedford H
Vaccine; 2003 Jun; 21(21-22):2877-81. PubMed ID: 12798630
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine.
Bårnes GK; Kristiansen PA; Beyene D; Workalemahu B; Fissiha P; Merdekios B; Bohlin J; Préziosi MP; Aseffa A; Caugant DA
BMC Infect Dis; 2016 Nov; 16(1):639. PubMed ID: 27814682
[TBL] [Abstract][Full Text] [Related]
27. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
28. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
29. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
30. Immunisation update: Meningococcal B and ACWY vaccines.
Davidson GT; Heaton PA; Paul SP
J Fam Health; 2015; 25(6):22-5. PubMed ID: 26749934
[No Abstract] [Full Text] [Related]
31. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
32. Meningococcal disease in New Zealand.
Mills G; Bell A
N Z Med J; 2013 Apr; 126(1373):10-1. PubMed ID: 23797072
[No Abstract] [Full Text] [Related]
33. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
34. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
Mooney JD; Christie P; Robertson C; Clarke SC
Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
[TBL] [Abstract][Full Text] [Related]
35. Meningococcal Disease: Vaccines-Who's at Risk and the Future.
O'Malley PA
Clin Nurse Spec; 2018; 32(1):15-18. PubMed ID: 29200035
[No Abstract] [Full Text] [Related]
36. Impact of vaccination on meningococcal epidemiology.
Stefanelli P; Rezza G
Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
[TBL] [Abstract][Full Text] [Related]
37. [Epidemiology of the meningococcal disease in Catalonia before and after vaccination against serogroup C].
Martínez AI; Domínguez A; Oviedo M; Minguell S; Jansà JM; Codina G; Vázquez JA;
Rev Esp Salud Publica; 2009; 83(5):725-35. PubMed ID: 20111820
[TBL] [Abstract][Full Text] [Related]
38. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
